ImmunityBio Signs Exclusive Agreement for BCG Supply with Japan Lab
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IBRX?
Source: stocktwits
- FDA Workshop Significance: ImmunityBio's founder Soon-Shiong described Monday's FDA workshop as a 'pivotal meeting' that will address whether CIS and papillary bladder cancer are different forms of the same disease, which could broaden Anktiva's indications and impact a larger patient population.
- BCG Supply Agreement: ImmunityBio signed an exclusive agreement with Japan BCG Laboratory for the Tokyo-172 strain, granting rights to develop and commercialize this strain in the U.S., aimed at addressing the long-standing supply shortages of bladder cancer treatments and enhancing market competitiveness.
- Immunotherapy 2.0 Initiative: Soon-Shiong introduced the concept of 'Immunotherapy 2.0,' which combines IL-15, NK cells, and AI technology to enhance immune system activity, showcasing the company's forward-looking strategy in cancer treatment development.
- Investor Sentiment Optimistic: Despite IBRX's stock falling over 6% last week, investor sentiment on Stocktwits remains 'bullish,' with many expressing intentions to hold long-term, reflecting confidence in the company's future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.150
Low
5.00
Averages
7.33
High
9.00
Current: 8.150
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Signs Exclusive Agreement for BCG Supply with Japan Lab
- FDA Workshop Significance: ImmunityBio's founder Soon-Shiong described Monday's FDA workshop as a 'pivotal meeting' that will address whether CIS and papillary bladder cancer are different forms of the same disease, which could broaden Anktiva's indications and impact a larger patient population.
- BCG Supply Agreement: ImmunityBio signed an exclusive agreement with Japan BCG Laboratory for the Tokyo-172 strain, granting rights to develop and commercialize this strain in the U.S., aimed at addressing the long-standing supply shortages of bladder cancer treatments and enhancing market competitiveness.
- Immunotherapy 2.0 Initiative: Soon-Shiong introduced the concept of 'Immunotherapy 2.0,' which combines IL-15, NK cells, and AI technology to enhance immune system activity, showcasing the company's forward-looking strategy in cancer treatment development.
- Investor Sentiment Optimistic: Despite IBRX's stock falling over 6% last week, investor sentiment on Stocktwits remains 'bullish,' with many expressing intentions to hold long-term, reflecting confidence in the company's future growth prospects.
See More
US Stock Futures Decline as Oil Prices Rise Amid Iran Tensions
- Cautious Market Sentiment: US stock futures declined in overnight trading on Sunday, with Dow futures down 0.79%, S&P 500 futures down 0.70%, and Nasdaq 100 futures down 0.93%, reflecting investor concerns over renewed tensions in the Middle East following President Trump's remarks on Iran.
- Rising Oil Prices: Brent crude futures rose approximately 2.21% to $111.67 per barrel, while WTI crude futures increased by 2.83% to $108.40 per barrel, indicating heightened fears of disruptions to global oil supplies amid geopolitical tensions.
- Bond Yields Surge: The benchmark 10-year Treasury yield remained elevated at 4.629% following hotter-than-expected US inflation data, with economists noting that G7 government bond yields have surged to their highest levels in over 20 years, reflecting market reactions to rising oil prices and fiscal deficits.
- Asian Markets Decline: Asian markets opened lower on Monday, with the KOSPI, Nikkei 225, and SSE Composite Index all declining, illustrating the global market's response to the escalating tensions between the US and Iran.
See More
Class Action Filed Against ImmunityBio, Inc. for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain officers, aiming to recover damages for investors who purchased the company's securities between January 19 and March 24, 2026, reflecting investor concerns over potential financial losses.
- Allegations of False Statements: The complaint alleges that the defendants materially overstated Anktiva's capabilities, resulting in misleading statements about ImmunityBio's business and prospects, which could have serious implications for investors' trust and financial outcomes.
- Investor Action Deadline: Investors must request to be appointed as lead plaintiff by May 26, 2026, to share in any potential recovery from the lawsuit, highlighting the urgency and significance of investor participation in the legal process.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers legal services on a contingency fee basis, meaning they only charge fees if they successfully recover funds, which reduces legal risks for investors and encourages more victims to join the lawsuit.
See More
ImmunityBio Secures Exclusive U.S. Rights for Bladder Cancer Therapy
- Licensing Agreement: ImmunityBio has secured a licensing deal with Japan BCG Laboratory to acquire exclusive U.S. rights for the bladder cancer treatment Bacillus Calmette-Guerin (BCG), marking a strategic expansion in the oncology sector.
- Clinical Trial Results: The Phase 3 trial results from February indicated that Tokyo strain BCG is non-inferior to FDA-approved TICE BCG in treating BCG-naïve high-grade non-muscle-invasive bladder cancer, enhancing the therapy's market potential.
- Market Expansion: Currently, ImmunityBio markets its immunotherapy Anktiva in the U.S. and plans to integrate the Tokyo strain BCG into its product offerings, which is expected to bolster the company's competitive position in the bladder cancer treatment market.
- Regulatory Submission Plans: As part of the agreement, ImmunityBio will file regulatory submissions to seek FDA approval and commercialization of the Tokyo strain BCG, demonstrating the company's commitment to new therapies and its intent to expand in the U.S. market.
See More
ImmunityBio Partners with Japan BCG Laboratory for Tokyo Strain
- Clinical Trial Success: The SWOG S1602 trial, sponsored by the National Cancer Institute, demonstrated that the Tokyo strain of BCG is non-inferior to TICE BCG in treating high-grade non-muscle invasive bladder cancer, with a hazard ratio of 0.82 against a pre-specified margin of 1.34, validating its efficacy.
- Exclusive Development Agreement: ImmunityBio has signed an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory, granting rights to develop, import, and commercialize the Tokyo strain of BCG, aiming to address the long-standing BCG shortage in the U.S. and significantly improve treatment options for patients.
- FDA Engagement Plans: ImmunityBio plans to engage with the FDA to expedite the approval process for the Tokyo strain of BCG, acting as the sole Biologics License Application applicant, which, if approved, will solidify its position in the bladder cancer treatment market.
- Ongoing Partnerships: The collaboration with Serum Institute of India ensures the availability of recombinant BCG (rBCG) under the FDA Expanded Access Program for eligible patients, aiming to alleviate the BCG shortage in the U.S. through dual supply sources.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading efficacy claims made by its Chief Scientific Officer regarding Anktiva, affecting investors who purchased shares between January 19 and March 24, 2026.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that promotional materials falsely suggested Anktiva could treat all cancers, with no supporting data, which severely undermines the company's credibility.
- Stock Price Plunge: Following this news, ImmunityBio's stock price dropped over 21% on March 24, 2026, erasing nearly $2 billion in market capitalization, indicating significant market concern about the company's future prospects.
- Investor Rights: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered substantial losses to report their losses for potential legal recourse.
See More
ImmunityBio Signs Exclusive Agreement for BCG Supply with Japan Lab
- FDA Workshop Significance: ImmunityBio's founder Soon-Shiong described Monday's FDA workshop as a 'pivotal meeting' that will address whether CIS and papillary bladder cancer are different forms of the same disease, which could broaden Anktiva's indications and impact a larger patient population.
- BCG Supply Agreement: ImmunityBio signed an exclusive agreement with Japan BCG Laboratory for the Tokyo-172 strain, granting rights to develop and commercialize this strain in the U.S., aimed at addressing the long-standing supply shortages of bladder cancer treatments and enhancing market competitiveness.
- Immunotherapy 2.0 Initiative: Soon-Shiong introduced the concept of 'Immunotherapy 2.0,' which combines IL-15, NK cells, and AI technology to enhance immune system activity, showcasing the company's forward-looking strategy in cancer treatment development.
- Investor Sentiment Optimistic: Despite IBRX's stock falling over 6% last week, investor sentiment on Stocktwits remains 'bullish,' with many expressing intentions to hold long-term, reflecting confidence in the company's future growth prospects.
See More
US Stock Futures Decline as Oil Prices Rise Amid Iran Tensions
- Cautious Market Sentiment: US stock futures declined in overnight trading on Sunday, with Dow futures down 0.79%, S&P 500 futures down 0.70%, and Nasdaq 100 futures down 0.93%, reflecting investor concerns over renewed tensions in the Middle East following President Trump's remarks on Iran.
- Rising Oil Prices: Brent crude futures rose approximately 2.21% to $111.67 per barrel, while WTI crude futures increased by 2.83% to $108.40 per barrel, indicating heightened fears of disruptions to global oil supplies amid geopolitical tensions.
- Bond Yields Surge: The benchmark 10-year Treasury yield remained elevated at 4.629% following hotter-than-expected US inflation data, with economists noting that G7 government bond yields have surged to their highest levels in over 20 years, reflecting market reactions to rising oil prices and fiscal deficits.
- Asian Markets Decline: Asian markets opened lower on Monday, with the KOSPI, Nikkei 225, and SSE Composite Index all declining, illustrating the global market's response to the escalating tensions between the US and Iran.
See More
Class Action Filed Against ImmunityBio, Inc. for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain officers, aiming to recover damages for investors who purchased the company's securities between January 19 and March 24, 2026, reflecting investor concerns over potential financial losses.
- Allegations of False Statements: The complaint alleges that the defendants materially overstated Anktiva's capabilities, resulting in misleading statements about ImmunityBio's business and prospects, which could have serious implications for investors' trust and financial outcomes.
- Investor Action Deadline: Investors must request to be appointed as lead plaintiff by May 26, 2026, to share in any potential recovery from the lawsuit, highlighting the urgency and significance of investor participation in the legal process.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers legal services on a contingency fee basis, meaning they only charge fees if they successfully recover funds, which reduces legal risks for investors and encourages more victims to join the lawsuit.
See More
ImmunityBio Secures Exclusive U.S. Rights for Bladder Cancer Therapy
- Licensing Agreement: ImmunityBio has secured a licensing deal with Japan BCG Laboratory to acquire exclusive U.S. rights for the bladder cancer treatment Bacillus Calmette-Guerin (BCG), marking a strategic expansion in the oncology sector.
- Clinical Trial Results: The Phase 3 trial results from February indicated that Tokyo strain BCG is non-inferior to FDA-approved TICE BCG in treating BCG-naïve high-grade non-muscle-invasive bladder cancer, enhancing the therapy's market potential.
- Market Expansion: Currently, ImmunityBio markets its immunotherapy Anktiva in the U.S. and plans to integrate the Tokyo strain BCG into its product offerings, which is expected to bolster the company's competitive position in the bladder cancer treatment market.
- Regulatory Submission Plans: As part of the agreement, ImmunityBio will file regulatory submissions to seek FDA approval and commercialization of the Tokyo strain BCG, demonstrating the company's commitment to new therapies and its intent to expand in the U.S. market.
See More
ImmunityBio Partners with Japan BCG Laboratory for Tokyo Strain
- Clinical Trial Success: The SWOG S1602 trial, sponsored by the National Cancer Institute, demonstrated that the Tokyo strain of BCG is non-inferior to TICE BCG in treating high-grade non-muscle invasive bladder cancer, with a hazard ratio of 0.82 against a pre-specified margin of 1.34, validating its efficacy.
- Exclusive Development Agreement: ImmunityBio has signed an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory, granting rights to develop, import, and commercialize the Tokyo strain of BCG, aiming to address the long-standing BCG shortage in the U.S. and significantly improve treatment options for patients.
- FDA Engagement Plans: ImmunityBio plans to engage with the FDA to expedite the approval process for the Tokyo strain of BCG, acting as the sole Biologics License Application applicant, which, if approved, will solidify its position in the bladder cancer treatment market.
- Ongoing Partnerships: The collaboration with Serum Institute of India ensures the availability of recombinant BCG (rBCG) under the FDA Expanded Access Program for eligible patients, aiming to alleviate the BCG shortage in the U.S. through dual supply sources.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading efficacy claims made by its Chief Scientific Officer regarding Anktiva, affecting investors who purchased shares between January 19 and March 24, 2026.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that promotional materials falsely suggested Anktiva could treat all cancers, with no supporting data, which severely undermines the company's credibility.
- Stock Price Plunge: Following this news, ImmunityBio's stock price dropped over 21% on March 24, 2026, erasing nearly $2 billion in market capitalization, indicating significant market concern about the company's future prospects.
- Investor Rights: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered substantial losses to report their losses for potential legal recourse.
See More
